Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
 
review article

Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

Jamshidi, Elham
•
Asgary, Amirhossein
•
Shafiekhani, Paria
Show more
April 14, 2022
Human Vaccines & Immunotherapeutics

It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineModified Letter Turned Commas antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.

  • Details
  • Metrics
Type
review article
DOI
10.1080/21645515.2022.2037384
Web of Science ID

WOS:000782353400001

Author(s)
Jamshidi, Elham
Asgary, Amirhossein
Shafiekhani, Paria
Khajeamiri, Yasaman
Mohamed, Kawthar
Esmaily, Hadi
Jamal Rahi, Sahand
Mansouri, Nahal  
Date Issued

2022-04-14

Publisher

TAYLOR & FRANCIS INC

Published in
Human Vaccines & Immunotherapeutics
Volume

18

Issue

5

Article Number

2037384

Subjects

Biotechnology & Applied Microbiology

•

Immunology

•

covid-19

•

vaccines

•

sars-cov-2

•

immunogenicity

•

humoral immunity

•

cell-mediated immunity

•

antibody persistence

•

long-term protection

•

long-term immunity

•

quality

•

disease

•

trials

Editorial or Peer reviewed

REVIEWED

Written at

EPFL

EPFL units
UPDEPALMA  
Available on Infoscience
April 25, 2022
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/187382
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés